progressionandmetastasis详解.PDFVIP

342 Cheng et al. / J Zhejiang Univ-Sci B (Biomed Biotechnol) 2016 17(5):342-351 Journal of Zhejiang University-SCIENCE B (Biomedicine Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) /jzus; E-mail: jzus@ Review: Chemokines and their receptors in lung cancer * progression and metastasis Zeng-hui CHENG1,2 1 1 3 †‡3 †‡1 , Yu-xin SHI , Min YUAN , Dan XIONG , Jiang-hua ZHENG , Zhi-yong ZHANG 1 ( Department of Radiology, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China) (2Department of Radiology, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China) (3Department of Clinical Laboratory, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China) †E-mail: zhengjianghua2014@163.com; zhangzy@ Received Oct. 27, 2015; Revision accepted Jan. 5, 2016; Crosschecked Apr. 15, 2016 Abstract: Lung cancer is the leading cause of cancer-related mortality around the world. Despite advancements in diagnosis, surgical techniques, and neoadjuvant chemoradiotherapy over the last decade, the mortality rate is still high and the 5-year survival is a dismal 15%. Fortunately, early detection by low-dose computed tomography (LDCT) scans has reduced mortality by 20%; yet, overall, 5-year-survival remains low at less than 20%. Therefore, in order to ame- liorate this situation, a thorough understanding of the underlying molecular mechanisms is urgently needed. C